News & Updates

Show Multimedia Only

Chemo plus targeted therapy extends survival in advanced BRAF-mutated CRC

The combination of chemotherapy and anti-EGFR/BRAF therapy provides optimal survival benefits to patients with advanced BRAF-mutated colorectal cancer (CRC), according to a study.

Chemo plus targeted therapy extends survival in advanced BRAF-mutated CRC

23 hours ago

Tinengotinib shows promising activity against cholangiocarcinoma

a day ago

In patients with cholangiocarcinoma with FGFR2 fusions that progressed following FGFR inhibitor therapy, tinengotinib has demonstrated potential antitumour activity in a phase II study.

Tinengotinib shows promising activity against cholangiocarcinoma

a day ago

Transfusion independence and improvements in symptoms and splenomegaly in two patients with PMF and anaemia treated with a JAK inhibitor

13 Dec 2025 by

A 52-year-old female presented with leukocytosis and thrombocytosis, and was diagnosed with primary myelofibrosis (PMF) in 2019. She had no significant past medical history and no anaemia at initial diagnosis. Molecular testing identified a type 2 calreticulin (CALR) mutation, and risk stratification using Dynamic International Prognostic Scoring System (DIPSS)-plus classified her as having very low-risk PMF. At that time, she was considered to be in the early phase of the disease.

Transfusion independence and improvements in symptoms and splenomegaly in two patients with PMF and anaemia treated with a JAK inhibitor

13 Dec 2025

Achieving very good PR with lorlatinib and managing AEs in an ALK-positive NSCLC patient with high tumour burden

12 Dec 2025 by

A 60-year-old female homemaker, never-smoker and never-drinker, with good past health, presented in March 2024 with persistent cough and progressively worsening shortness of breath of 3 weeks following COVID-19 infection. Physical examination revealed an enlarged left supraclavicular lymph node (LN) of approximately 2.5 cm. Chest X-ray (CXR) showed a shadow in the left upper lobe (LUL) of the lung.

Achieving very good PR with lorlatinib and managing AEs in an ALK-positive NSCLC patient with high tumour burden

12 Dec 2025

Osimertinib plus chemo-therapy: A promising 1L option for high-risk EGFRm NSCLC

11 Dec 2025 by

The treatment landscape for EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) is rapidly evolving, with many exciting developments on the horizon. At a recent scientific symposium, experts in lung cancer gathered to review the latest advances. This article highlights the key takeaways from the symposium, summarizing FLAURA2 trial data presented by Professor Natalia Valdiviezo from San Ignacio de Loyola University, Lima, Peru, and main insights from the panel discussion led by Dr Herbert Loong from the Department of Clinical Oncology, the Chinese University of Hong Kong, with contributions from Dr James Ho of the Department of Medicine, University of Hong Kong, and Dr Michael Kam, Specialist in Clinical Oncology in Hong Kong.

Osimertinib plus chemo-therapy: A promising 1L option for high-risk EGFRm NSCLC

11 Dec 2025

Achieving ultra-low PSA levels with ADT plus ARPI improves mHSPC outcomes in a patient with comorbidities

11 Dec 2025 by

A 70-year-old male was diagnosed with prostate cancer (PC) after presenting with increased urinary frequency and an elevated prostate-specific antigen (PSA) level of 71 ng/mL in October 2022. (Figure) MRI revealed a 3 cm left prostatic lesion without pelvic lymph node involvement or bone metastases, with possible extraprostatic extension and seminal vesicle invasion. Transperineal ultrasound-guided prostate biopsy confirmed prostatic adenocarcinoma in 8 out of 12 cores, with a Gleason score of 4 + 3.

Achieving ultra-low PSA levels with ADT plus ARPI improves mHSPC outcomes in a patient with comorbidities

11 Dec 2025

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

11 Dec 2025 by

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options and historically poor outcomes. Prior to the emergence of antibody–drug conjugates (ADCs), palliative sequential single-agent chemotherapy was the mainstay of treatment for metastatic TNBC (mTNBC), offering limited response and survival. In an interview with MIMS Oncology, Dr Rodrigo Sánchez-Bayona from the Universitary Hospital 12 de Octubre, Madrid, Spain, discussed how Trop-2–targeted ADCs have changed the treatment landscape of mTNBC and predicted their future role in the changing treatment paradigm. He highlighted data on sacituzumab govitecan (SG), an ADC that has demonstrated efficacy regardless of Trop-2 expression status or presence of biomarkers while maintaining quality of life (QoL), and shared a patient case with rapidly progressing mTNBC effectively treated with SG.

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

11 Dec 2025

Dual IO sets new standard in first-line MSI-H/dMMR mCRC

09 Dec 2025 by

Immune checkpoint inhibitors have substantially improved prognosis of patients with metastatic colorectal cancer (mCRC) characterized by microsatellite instability-high (MSI-H) status or mismatch repair deficiency (dMMR). At an industry-sponsored meeting organized by the Hong Kong Society of Digestive Oncology, Professor Heinz-Josef Lenz of the USC Norris Comprehensive Cancer Center in Los Angeles, California, US, discussed updated results of the phase III CheckMate 8HW trial, which support the paradigm shift in favour of first-line dual immunotherapy (IO) with nivolumab plus ipilimumab vs monotherapy and chemotherapy for patients with MSI-H/dMMR mCRC.

Dual IO sets new standard in first-line MSI-H/dMMR mCRC

09 Dec 2025

PPI use hurts survival outcomes in glioblastoma

08 Dec 2025

In patients with newly diagnosed glioblastoma, the use proton pump inhibitors (PPI) may be detrimental to survival, according to a meta-analysis.

PPI use hurts survival outcomes in glioblastoma

08 Dec 2025

Liver transplant tied to better survival than systemic therapy only in nonmetastatic HCC

07 Dec 2025

In patients with nonmetastatic hepatocellular carcinoma (HCC), treatment with upfront liver transplant or liver transplant with bridge systemic therapy results in significantly better improvements in overall survival (OS) compared with systemic therapy only, according to a study.

Liver transplant tied to better survival than systemic therapy only in nonmetastatic HCC

07 Dec 2025

News & Updates

Filter by Specialty:

Specialty:

Chemo plus targeted therapy extends survival in advanced BRAF-mutated CRC

Chemo plus targeted therapy extends survival in advanced BRAF-mutated CRC

Tinengotinib shows promising activity against cholangiocarcinoma

Tinengotinib shows promising activity against cholangiocarcinoma

Transfusion independence and improvements in symptoms and splenomegaly in two patients with PMF and anaemia treated with a JAK inhibitor

Transfusion independence and improvements in symptoms and splenomegaly in two patients with PMF and anaemia treated with a JAK inhibitor

Achieving very good PR with lorlatinib and managing AEs in an ALK-positive NSCLC patient with high tumour burden

Achieving very good PR with lorlatinib and managing AEs in an ALK-positive NSCLC patient with high tumour burden

Osimertinib plus chemo-therapy: A promising 1L option for high-risk EGFRm NSCLC

Osimertinib plus chemo-therapy: A promising 1L option for high-risk EGFRm NSCLC

Achieving ultra-low PSA levels with ADT plus ARPI improves mHSPC outcomes in a patient with comorbidities

Achieving ultra-low PSA levels with ADT plus ARPI improves mHSPC outcomes in a patient with comorbidities

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

Dual IO sets new standard in first-line MSI-H/dMMR mCRC

Dual IO sets new standard in first-line MSI-H/dMMR mCRC

PPI use hurts survival outcomes in glioblastoma

PPI use hurts survival outcomes in glioblastoma

Liver transplant tied to better survival than systemic therapy only in nonmetastatic HCC

Liver transplant tied to better survival than systemic therapy only in nonmetastatic HCC